Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 29, 2022 08:00 ET | Source: Candel Therapeutics

Candel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight...
March 02, 2022 08:00 ET | Source: Candel Therapeutics

Candel Therapeutics Appoints Seshu Tyagarajan, Ph.D., RAC, as Chief Technical and Development Officer

NEEDHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
March 01, 2022 08:00 ET | Source: Candel Therapeutics

Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank

Additional capital extends cash runway into Q4 of 2023 NEEDHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL) (the “Company” or “Candel”), a late clinical stage...
February 03, 2022 08:00 ET | Source: Candel Therapeutics

Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer

NEEDHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
January 05, 2022 08:00 ET | Source: Candel Therapeutics

Candel Therapeutics to Present at Two Upcoming Investor Conferences

NEEDHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
December 15, 2021 05:00 ET | Source: Candel Therapeutics

Bionaut Labs and Candel Therapeutics Announce Strategic Collaboration in Precision-Targeted Delivery of Oncolytic Viral Immunotherapies

Companies will work on preclinical development of remote-controlled microscale robots to deliver novel oncolytic viral immunotherapies in specific brain tumors LOS ANGELES and NEEDHAM, Mass., Dec. ...
December 10, 2021 08:00 ET | Source: Candel Therapeutics

Candel Therapeutics and Partnership for Accelerating Cancer Therapies (PACT) to Collaborate on Lung Cancer Trial for CAN-2409

Partnership for Accelerating Cancer Therapies to conduct extensive biomarker analysis for ongoing phase 2 clinical trial in non-small cell lung cancerTrial combines CAN-2409 with immune checkpoint...
November 12, 2021 08:00 ET | Source: Candel Therapeutics

Candel Therapeutics Presents Novel Biomarker Data Demonstrating Immune Activation After Administration of CAN-3110 in Patients with Recurrent High-Grade Glioma

Data presented at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual MeetingIntra-tumoral administration of CAN-3110 elicited significant T-cell infiltration and expansion of T-cell...
November 12, 2021 08:00 ET | Source: Candel Therapeutics

Candel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel” or “the Company”) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic...
November 02, 2021 08:00 ET | Source: Candel Therapeutics

Candel Therapeutics to Participate in Three Upcoming Investor Conferences

NEEDHAM, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...